-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
A -X- _ O
novel -X- _ O
, -X- _ O
swine-origin -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1 -X- _ O
) -X- _ O
virus -X- _ O
was -X- _ O
detected -X- _ O
worldwide -X- _ O
in -X- _ O
April -X- _ O
2009 -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
World -X- _ O
Health -X- _ O
Organization -X- _ O
( -X- _ O
WHO -X- _ O
) -X- _ O
declared -X- _ O
a -X- _ O
global -X- _ O
pandemic -X- _ O
that -X- _ O
June. -X- _ O
DNA -X- _ O
vaccine -X- _ O
priming -X- _ O
improves -X- _ O
responses -X- _ O
to -X- _ O
inactivated -X- _ O
influenza -X- _ O
vaccines. -X- _ O
We -X- _ O
describe -X- _ O
the -X- _ O
rapid -X- _ O
production -X- _ O
and -X- _ O
clinical -X- _ O
evaluation -X- _ O
of -X- _ O
a -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
encoding -X- _ I-Intervention
the -X- _ I-Intervention
hemagglutinin -X- _ I-Intervention
protein -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
2009 -X- _ I-Intervention
pandemic -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
California -X- _ I-Intervention
/ -X- _ I-Intervention
04 -X- _ I-Intervention
/ -X- _ I-Intervention
2009 -X- _ I-Intervention
( -X- _ I-Intervention
H1N1 -X- _ I-Intervention
) -X- _ I-Intervention
influenza -X- _ I-Intervention
virus -X- _ I-Intervention
, -X- _ O
accomplished -X- _ O
nearly -X- _ O
two -X- _ O
months -X- _ O
faster -X- _ O
than -X- _ O
production -X- _ O
of -X- _ O
A -X- _ B-Intervention
/ -X- _ I-Intervention
California -X- _ I-Intervention
/ -X- _ I-Intervention
07 -X- _ I-Intervention
/ -X- _ I-Intervention
2009 -X- _ I-Intervention
( -X- _ I-Intervention
H1N1 -X- _ I-Intervention
) -X- _ I-Intervention
licensed -X- _ I-Intervention
monovalent -X- _ I-Intervention
inactivated -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
MIV -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
METHODS -X- _ O
: -X- _ O
20 -X- _ B-Patient
subjects -X- _ I-Patient
received -X- _ O
three -X- _ O
H1 -X- _ O
DNA -X- _ O
vaccinations -X- _ O
( -X- _ O
4 -X- _ O
mg -X- _ O
intramuscularly -X- _ O
with -X- _ O
Biojector -X- _ O
) -X- _ O
at -X- _ O
4-week -X- _ O
intervals. -X- _ O
Eighteen -X- _ O
subjects -X- _ O
received -X- _ O
an -X- _ O
optional -X- _ O
boost -X- _ O
when -X- _ O
the -X- _ O
licensed -X- _ O
H1N1 -X- _ O
MIV -X- _ O
became -X- _ O
available. -X- _ O
The -X- _ O
interval -X- _ O
between -X- _ O
the -X- _ O
third -X- _ O
H1 -X- _ O
DNA -X- _ O
injection -X- _ O
and -X- _ O
MIV -X- _ O
boost -X- _ O
was -X- _ O
3â€“17 -X- _ O
weeks. -X- _ O
Vaccine -X- _ O
safety -X- _ O
was -X- _ O
assessed -X- _ O
by -X- _ O
clinical -X- _ O
observation -X- _ O
, -X- _ O
laboratory -X- _ O
parameters -X- _ O
, -X- _ O
and -X- _ O
7-day -X- _ O
solicited -X- _ O
reactogenicity. -X- _ O
Antibody -X- _ O
responses -X- _ O
were -X- _ O
assessed -X- _ O
by -X- _ O
ELISA -X- _ O
, -X- _ O
HAI -X- _ O
and -X- _ O
neutralization -X- _ O
assays -X- _ O
, -X- _ O
and -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
by -X- _ O
ELISpot -X- _ O
and -X- _ O
flow -X- _ O
cytometry. -X- _ O
RESULTS -X- _ O
: -X- _ O
Vaccinations -X- _ O
were -X- _ O
safe -X- _ O
and -X- _ O
well-tolerated. -X- _ O
As -X- _ O
evaluated -X- _ O
by -X- _ O
HAI -X- _ O
, -X- _ O
6 -X- _ O
/ -X- _ O
20 -X- _ O
developed -X- _ O
positive -X- _ O
responses -X- _ O
at -X- _ O
4 -X- _ O
weeks -X- _ O
after -X- _ O
third -X- _ O
DNA -X- _ O
injection -X- _ O
and -X- _ O
13 -X- _ O
/ -X- _ O
18 -X- _ O
at -X- _ O
4 -X- _ O
weeks -X- _ O
after -X- _ O
MIV -X- _ O
boost. -X- _ O
Similar -X- _ O
results -X- _ O
were -X- _ O
detected -X- _ O
in -X- _ O
neutralization -X- _ O
assays. -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
were -X- _ O
detected -X- _ O
after -X- _ O
DNA -X- _ O
and -X- _ O
MIV. -X- _ O
The -X- _ O
antibody -X- _ O
responses -X- _ O
were -X- _ O
significantly -X- _ O
amplified -X- _ O
by -X- _ O
the -X- _ O
MIV -X- _ O
boost -X- _ O
, -X- _ O
however -X- _ O
, -X- _ O
the -X- _ O
boost -X- _ O
did -X- _ O
not -X- _ O
increased -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
induced -X- _ O
by -X- _ O
DNA -X- _ O
vaccine. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
H1 -X- _ B-Outcome
DNA -X- _ I-Outcome
vaccine -X- _ I-Outcome
was -X- _ I-Outcome
produced -X- _ I-Outcome
quickly -X- _ I-Outcome
, -X- _ I-Outcome
was -X- _ I-Outcome
well-tolerated -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
had -X- _ I-Outcome
modest -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
agent. -X- _ I-Outcome
Other -X- _ O
HA -X- _ O
DNA -X- _ O
prime-MIV -X- _ O
boost -X- _ O
regimens -X- _ O
utilizing -X- _ O
one -X- _ O
DNA -X- _ O
prime -X- _ O
vaccination -X- _ O
and -X- _ O
longer -X- _ O
boost -X- _ O
intervals -X- _ O
have -X- _ O
shown -X- _ O
significant -X- _ O
immunogenicity. -X- _ O
Rapid -X- _ B-Outcome
and -X- _ I-Outcome
large-scale -X- _ I-Outcome
production -X- _ I-Outcome
of -X- _ I-Outcome
HA -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccines -X- _ I-Outcome
has -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
to -X- _ I-Outcome
contribute -X- _ I-Outcome
to -X- _ I-Outcome
an -X- _ I-Outcome
efficient -X- _ I-Outcome
response -X- _ I-Outcome
against -X- _ I-Outcome
future -X- _ I-Outcome
influenza -X- _ I-Outcome
pandemics. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Clinicaltrials.gov -X- _ O
NCT00973895 -X- _ O

